(NASDAQ: MIST) Milestone Pharmaceuticals's forecast annual revenue growth rate of 291.8% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.08%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.19%.
Milestone Pharmaceuticals's revenue in 2026 is $1,546,000.On average, 7 Wall Street analysts forecast MIST's revenue for 2026 to be $3,189,606,878, with the lowest MIST revenue forecast at $461,255,726, and the highest MIST revenue forecast at $10,057,022,165. On average, 6 Wall Street analysts forecast MIST's revenue for 2027 to be $3,582,615,583, with the lowest MIST revenue forecast at $2,421,592,561, and the highest MIST revenue forecast at $4,942,025,634.
In 2028, MIST is forecast to generate $12,662,175,678 in revenue, with the lowest revenue forecast at $7,380,091,613 and the highest revenue forecast at $21,214,233,370.